Suppr超能文献

头孢泊肟酯作为儿童感染性心内膜炎转换治疗的一种治疗选择:病例报告与文献综述

Cefpodoxime proxetil as a therapeutic option in switching therapy for infective endocarditis in children: case reports and literature review.

作者信息

Krajcar Nina, Marić Lorna Stemberger, Šarić Dalibor, Milić Neven, Tešović Goran

机构信息

University Hospital for Infectious Diseases, 'Dr. Fran Mihaljević ', Zagreb , Croatia.

School of Dental Medicine, University of Zagreb , Zagreb , Croatia.

出版信息

J Chemother. 2019 Oct;31(6):354-358. doi: 10.1080/1120009X.2019.1603797. Epub 2019 Apr 22.

Abstract

Infective endocarditis (IE) is uncommon in children, affecting predominantly subjects with congenital heart disease (CHD) and patients with indwelling central lines. The principles of antibiotic treatment in paediatric population are similar to those in adults. Prolonged intravenous administration of bactericidal rather than bacteriostatic agents is preferred. Outpatient intravenous therapy after initial treatment in the hospital may be considered only in selected patients. Partial oral treatment has been described in cases of left-sided, uncomplicated IE caused by common pathogens in adult patients. There are no guidelines or trials in paediatric population regarding switching therapy from intravenous to oral route. We present two cases of IE in children caused by uncommon pathogenic bacteria ( and ) successfully treated with oral third-generation cephalosporin - cefpodoxime proxetil after initial intravenous therapy. This paper provides observations on different therapeutic approach for IE in children as well as another potential use of cefpodoxime proxetil.

摘要

感染性心内膜炎(IE)在儿童中并不常见,主要影响患有先天性心脏病(CHD)的患者和留置中心静脉导管的患者。儿科人群抗生素治疗的原则与成人相似。首选长时间静脉注射杀菌而非抑菌药物。仅在选定的患者中可考虑在医院初始治疗后进行门诊静脉治疗。在成年患者中,对于由常见病原体引起的左侧、无并发症的IE病例,已有部分口服治疗的报道。在儿科人群中,尚无关于从静脉途径转换为口服途径治疗的指南或试验。我们报告了两例由罕见病原菌引起的儿童IE病例( 和 ),在初始静脉治疗后成功采用口服第三代头孢菌素头孢泊肟酯进行治疗。本文提供了关于儿童IE不同治疗方法的观察结果以及头孢泊肟酯的另一种潜在用途。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验